03 September 2024
03 September 2024
The US regulatory agency has also approved updated versions of Moderna and Pfizer / BioNTech’s Covid-19 vaccines in the past two weeks.
The initiative is part of a broader strategy to promote public health.
The move is part of the NHS's winter 2024 preparedness efforts.
Nxera will receive $35m from Neurocrine due to the successful completion of the Phase II trial of NBI-568 in schizophrenia.
New insights on the PACMAN-AMI trial for patients with acute myocardial infarction are presented at the ESC Congress, among other updates.
LAZCLUZE along with RYBREVANT demonstrated superior progression-free survival in clinical studies.
The companies will work together at the AI Bio Supercomputer Center in Daejeon.
TargetRx is entitled to an upfront payment of $20m and will be compensated for promotional efforts.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
